Cherry Hill, NJ, United States of America

Robert Korngold

USPTO Granted Patents = 10 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 91(Granted Patents)

Company Filing History:

9 out of 528

Thomas Jefferson University

1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2008

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7345020 - Mimetics of CD4 that inhibit immune response (2008-03-18),

2. 6844421 - CD4-derived peptides that inhibit immune response (2005-01-18),

3. 6346602 - Peptide mimics of the cytokine receptor common &ggr; chain and methods and compositions for making and using the same (2002-02-12),

4. 6180600 - CD8 antagonists (2001-01-30),

5. 6127387 - Use of CD4-binding small molecules to inhibit immune responses (2000-10-03),

6. 5962634 - IgE antagonists (1999-10-05),

7. 5958882 - Compounds that inhibit T cell proliferation and methods using the same (1999-09-28),

8. 5846933 - CD-4 derived peptides that inhibit immune responses (1998-12-08),

9. 5645837 - Peptides that inhibit T cell activation and methods of using the same (1997-07-08),

10. 5589458 - Compounds that inhibit T cell proliferation and methods for using the (1996-12-31),

Title: The Innovative Contributions of Robert Korngold

Introduction

Robert Korngold is a notable inventor based in Cherry Hill, NJ (US). He has made significant contributions to the field of immunology, particularly in developing methods to inhibit undesired immune responses. With a total of 10 patents to his name, Korngold's work has the potential to impact treatments for various diseases.

Latest Patents

Korngold's latest patents focus on mimetics of CD4 that inhibit immune response. The application details a method for identifying compounds that can block the interaction of CD4 and MHC, class II, gene products. This method aims to treat diseases such as multiple sclerosis and prevent graft rejection and graft versus host disease. The compounds he has developed mimic specific portions of the human CD4 lymphocyte cell surface antigen, with molecular weights ranging from about 1400 to 400. Examples of these compounds include cyclic peptides and peptidomimetics.

Career Highlights

Throughout his career, Korngold has worked at Thomas Jefferson University, where he has contributed to groundbreaking research in immunology. His innovative approaches have garnered attention in the scientific community, leading to advancements in therapeutic strategies.

Collaborations

Korngold has collaborated with notable colleagues, including Ziwei Huang and Bradford A. Jameson. These partnerships have further enhanced the impact of his research and innovations.

Conclusion

Robert Korngold's contributions to immunology through his patents and research are noteworthy. His work continues to pave the way for new treatments and therapies that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.